- Home
- COYA vs IMAB Comparison
COYA vs IMAB Comparison
Compare COYA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COYA
- IMAB
- Stock Information
- Founded
- COYA 2020
- IMAB 2014
- Country
- COYA United States
- IMAB United States
- Employees
- COYA N/A
- IMAB N/A
- Industry
- COYA Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- COYA Health Care
- IMAB Health Care
- Exchange
- COYA Nasdaq
- IMAB Nasdaq
- Market Cap
- COYA 93.9M
- IMAB 83.8M
- IPO Year
- COYA 2022
- IMAB 2020
- Fundamental
- Price
- COYA $5.38
- IMAB $1.07
- Analyst Decision
- COYA Strong Buy
- IMAB Strong Buy
- Analyst Count
- COYA 4
- IMAB 3
- Target Price
- COYA $16.25
- IMAB $8.00
- AVG Volume (30 Days)
- COYA 62.0K
- IMAB 682.1K
- Earning Date
- COYA 11-06-2024
- IMAB 03-13-2025
- Dividend Yield
- COYA N/A
- IMAB N/A
- EPS Growth
- COYA N/A
- IMAB N/A
- EPS
- COYA N/A
- IMAB N/A
- Revenue
- COYA $9,554,315.00
- IMAB $3,313,984.00
- Revenue This Year
- COYA N/A
- IMAB N/A
- Revenue Next Year
- COYA $87.80
- IMAB N/A
- P/E Ratio
- COYA N/A
- IMAB N/A
- Revenue Growth
- COYA N/A
- IMAB N/A
- 52 Week Low
- COYA $4.75
- IMAB $0.84
- 52 Week High
- COYA $10.69
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- COYA 38.98
- IMAB 55.17
- Support Level
- COYA $5.52
- IMAB $1.00
- Resistance Level
- COYA $6.14
- IMAB $1.20
- Average True Range (ATR)
- COYA 0.44
- IMAB 0.12
- MACD
- COYA -0.01
- IMAB 0.02
- Stochastic Oscillator
- COYA 5.13
- IMAB 40.97
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).